Logo image
Back
RapidPlan hippocampal sparing whole brain model version 2-how far can we reduce the dose?
Journal article   Open access   Peer reviewed

RapidPlan hippocampal sparing whole brain model version 2-how far can we reduce the dose?

Hefei Liu, Ryan Clark, Anthony Magliari, Robert Foster, Francisco Reynoso, Matthew Schmidt, Vinai Gondi, Christopher Abraham, Heather Curry, Patrick Kupelian, …
Medical dosimetry : official journal of the American Association of Medical Dosimetrists, v 47(3), pp 258-263
01 Jan 2022
DOI: https://doi.org/10.1016/j.meddos.2022.04.003
PMID: 35513996
Featured in Collection :   UN Sustainable Development Goals @ Drexel
url
https://doi.org/10.1016/j.meddos.2022.04.003View
Published, Version of Record (VoR) Open

Abstract

Life Sciences & Biomedicine Oncology Radiology, Nuclear Medicine & Medical Imaging Science & Technology
Whole-brain radiotherapy has been the standard palliative treatment for patients with brain metastases due to its effectiveness, availability, and ease of administration. Recent clinical trials have shown that limiting radiation dose to the hippocampus is associated with decreased cognitive toxicity. In this study, we updated an existing Knowledge Based Planning model to further reduce dose to the hippocampus and improve other dosimetric plan quality characteristics. Forty-two clinical cases were contoured according to guidelines. A new dosimetric scorecard was created as an objective measure for plan quality. The new Hippocampal Sparing Whole Brain Version 2 (HSWBv2) model adopted a complex recursive training process and was validated with five additional cases. HSWBv2 treatment plans were generated on the Varian Halcyon TM and TrueBeam TM systems and compared against plans generated from the existing (HSWBv1) model released in 2016. On the Halcyon TM platform, 42 cases were re-planned. Hippocampal D 100% from HSWBv2 and HSWBv1 models had an average dose of 5.75 Gy and 6.46 Gy, respectively ( p < 0.001). HSWBv2 model also achieved a hippocampal D mean of 7.49 Gy, vs 8.10 Gy in HSWBv1 model ( p < 0.001). Hippocampal D 0.03CC from HSWBv2 model was 9.86 Gy, in contrast to 10.57 Gy in HSWBv1 ( p < 0.001). For PTV_30 0 0, D 98% and D 2% from HSWBv2 model were 28.27 Gy and 31.81 Gy, respectively, compared to 28.08 Gy ( p = 0.020) and 32.66 Gy from HSWBv1 ( p < 0.001). Among several other dosimetric quality improvements, there was a significant reduction in PTV_30 0 0 V 105% from 35.35% (HSWBv1) to 6.44% (HSWBv2) ( p < 0.001). On 5 additional validation cases, dosimetric improvements were also observed on TrueBeam TM . In comparison to published data, the HSWBv2 model achieved higher quality hippocampal avoidance whole brain radiation therapy treatment plans through further reductions in hippocampal dose while improving target coverage and dose conformity/homogeneity. HSWBv2 model is shared publicly. (c) 2022 The Authors. Published by Elsevier Inc. on behalf of American Association of Medical Dosimetrists. This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ )

Metrics

1 Record Views
18 citations in Web of Science
14 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Domestic collaboration
Web of Science research areas
Oncology
Radiology, Nuclear Medicine & Medical Imaging
Logo image